title: [The impact of immunosuppressive therapy on genetic instabilities of bone marrow hematopoietic cells in patients with aplastic anemia].
abstract: OBJECTIVE
  To investigate the impact of immunosuppressive therapy (IST) on genetic instabilities of bone marrow hematopoietic cells (BMHCs) in patients with aplastic anemia (AA).
  
  
  METHODS
  Comet assay as used to detect genetic instabilities of hematopoietic cells from patients, and the percent of DNA in comet tail (TDNA), tail length (TL), tail moment (TM), olive tail moment (OTM) and the rate of comet cells were measured. BMHCs from AA patients were examined with comet assay before and after IST, and the results were compared with those from controls.
  
  
  RESULTS
  Comet parameters from 91 AA patients including TDNA, TL, TM, OTM comet cell percentage were (5.0 +/- 4.0)%, 11.3 +/- 7.2, 1.7 +/- 2.0, 1.5 +/- 1.4, (16.8 +/- 13.7)%, respectively, which were significantly higher than those from control group (P < 0.05). There were statistical differences between the comet parameters of severe AA (SAA)/non-SAA (NSAA) and those of control group (P < 0.05), but no difference in the comet parameters between SAA and NSAA patients (P > 0.05). The TDNA, TL, TM, OTM and comet cells percentage were (4.4 +/- 3.6)%, 10.4 +/- 7.5, 1.4 +/- 1.6, 1.3 +/- 1.4 and (20.2 +/- 21.2)%, respectively at 3 months after IST in 53 SAA patients and were (3.7 +/- 3.3)%, 10.0 +/- 7.2, 1.2 +/- 1.8, 1.1 +/- 1.3 and (18.5 +/- 19.0)% respectively at 6 months after IST in 30 SAA patients, being no statistical difference from those of 58 SAA patients before IST (P values were all > 0.05).
  
  
  CONCLUSIONS
  BMHCs of AA had inherent genetic instabilities which were not increased by recent IST. It indicated that there was no correlation between IST and the development of clonal hematologic disorders in AA.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Li-hong
authors.initials: LH
authors.lastname: Zhang
authors.forename: Hui-jun
authors.initials: HJ
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Kang
authors.initials: K
authors.lastname: Zhou
authors.forename: Dong-lin
authors.initials: DL
authors.lastname: Yang
authors.forename: Zhang-song
authors.initials: ZS
authors.lastname: Yan
authors.forename: Hong-qiang
authors.initials: HQ
authors.lastname: Li
authors.forename: Qing-guo
authors.initials: QG
authors.lastname: Liu
authors.forename: Jun-yuan
authors.initials: JY
authors.lastname: Qi
authors.forename: Qiang
authors.initials: Q
authors.lastname: Liu
authors.forename: Yu-lin
authors.initials: YL
authors.lastname: Chu
authors.forename: Feng-kui
authors.initials: FK
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000235:genetics / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D020552:Comet Assay; D005260:Female; D042822:Genomic Instability; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents